Peer Reviewed
Drug update

Biological therapies for rheumatoid arthritis: TNF inhibitors

John Hy Moi, Russell Rc Buchanan
Abstract
The advent of TNF inhibitors represents a significant advance in treatment options for patients with rheumatoid arthritis who are refractory to traditional DMARD therapy.
Key Points

    Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder of unknown aetiology. It is the most common form of inflammatory arthritis and affects about 0.5 to 1% of the adult population worldwide. The peak incidence of disease onset occurs in people aged between 20 and 40 years, with women representing three-quarters of all those diagnosed with the condition.

Purchase the PDF version of this article
Purchase PDF AUD$34.99
Subscribe for full access to all articles
Already a subscriber?